Naftifine
From Infogalactic: the planetary knowledge core
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
(2E)-N-methyl-N-(1-naphthylmethyl)-3-phenylprop-2-en-1-amine
|
|
| Clinical data | |
| Trade names | Naftin |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a688020 |
| Identifiers | |
| CAS Number | 65472-88-0  |
| ATC code | D01AE22 (WHO) |
| PubChem | CID: 47641 |
| DrugBank | DB00735 |
| ChemSpider | 66071  |
| UNII | 4FB1TON47A |
| ChEBI | CHEBI:7451 |
| ChEMBL | CHEMBL626 |
| Chemical data | |
| Formula | C21H21N |
| Molecular mass | 287.398 g/mol |
| (what is this?) (verify) |
|
Naftifine (brand name Naftin) is an allylamine antifungal drug for the topical treatment of tinea pedis, tinea cruris, and tinea corporis (fungal infections).
Its precise mechanism of action is unknown, but may involve selectively blocking sterol biosynthesis via inhibition of the squalene 2,3-epoxidase enzyme.[1][2] The half-life is approximately 2–3 days.[2] The metabolites are excreted in the urine and feces.[3]
References
- ↑ Robertson Dirk B, Maibach Howard I, "Chapter 61. Dermatologic Pharmacology" (Chapter). Bertram G. Katzung, Susan B. Masters, Anthony J. Trevor: Basic & Clinical Pharmacology, 11e: http://www.accesspharmacy.com/content.aspx?aID=4517257.
- ↑ 2.0 2.1 Micromedex DRUGDEX Drug Point: Naftifine Hydrochloride. Accessed at www.thomsonhc.com/../BeginWith#secN10184, February 18, 2010.
- ↑ AccessPharmacy: Drug Monographs: Naftifine. Accessed at http://www.accesspharmacy.com/drugContentPopup.aspx?mid=6620§ion=10, February 18, 2010.
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |
